Summary
What do they do? Thriving Families provides MotherWise workshops and coaching for pregnant and new mothers. La Luz postpartum groups, WiseWellness counseling and parenting programs complement the core service. Childcare, transport and food supports help families participate; the recipient is separate from the University of Denver.
Why we’re interested in this organization:
A direct local randomized MotherWise evaluation tests outcomes against usual services rather than testimonials.
Original ROSE research supports a distinct depression-prevention mechanism, with explicit local transport limits.
The numerical reference matches historical full annual cost and enrollment and keeps clinical people separate from household resources.
Our main reservations:
Current unique completed participants by program, eligible La Luz recipients and Denver residence are unmeasured.
MotherWise did not clearly improve depression or material hardship in its direct follow-up, while prenatal ROSE differs from postpartum La Luz.
The price describes a conditional partial channel using whole recipient cost; counseling, parenting and relationship effects remain unknown, not zero.
What do you get for your dollar? $7.3M per DALY in Denver. DALY is our one-year comparison unit. QALY-based health gains and income-welfare equivalents retain their original assumptions; they are not measured clinical DALYs. Matched historical FY2023 whole recipient annual cost against a conditional La Luz prevention subset; not whole-portfolio or marginal-gift expected value..
Original FY2023 567 enrolled participants; meetings and counseling contacts overlap. FY2024 original program description gives no delivered annual count. Current six-week MotherWise and four-week/six-hour La Luz formats do not prove eligibility, completed preventive dose or net patient outcomes.
1. What do they do?
Thriving Families, EIN 84-1993572, independently operates MotherWise, La Luz, WiseWellness and parenting programs. MotherWise comprises six weeks of workshops plus individual coaching. WiseWellness serves individuals, couples and families; Incredible Years targets parents of children aged three to six. These programs are not separate legal charities or automatically independent beneficiary cohorts.
2. Monitoring and information sharing
The original FY2023 IRS filing reports 567 enrolled participants, 572 intakes, 644 support meetings and 1,720 counseling appointments, not 567 completed La Luz treatments. Current FY2024 original filing names programs but supplies no matched delivered cohort. The undated more-than-700 family claim is not substituted as observed annual output. Request annual distinct people and household IDs by program, prenatal versus postpartum eligibility, dose completion, clinical episodes, otherwise-paid expenses, employment/benefit changes and ten-county CBSA19740 residence. Track relationship outcomes separately from QALYs or earnings.
3. Qualitative assessment
The direct original MotherWise evaluation randomized 949 expectant/new mothers; 748 responded at 30 months. It tested six weekly four-hour groups plus case management and optional couples work against usual services. Relationship skills and stability improved, but depression at one year/30 months and material hardship at 30 months did not show clear benefits. This is important contrary evidence to inferring clinical or work gains from improved relationships. It does not establish zero lifetime or other program effects. The separate original ROSE trial randomized 205 at-risk pregnant adults on public assistance and reported six-month depression incidence of 16% versus 31%. La Luz is currently four weeks/six hours and described as postpartum education, so prenatal timing, eligibility, dose and preventive applicability remain material uncertainties. The .15 ITT difference is retained only as an explicit transfer hypothesis within a judged quarter of enrollment. The legacy completion=.7 parameter is a judged dose/fidelity transport factor relative to trial assignment, not a second observed completion rate or per-completer efficacy; the trial itself averaged 3.5 of five sessions. Completion=1 declines that extra transport haircut. Utility loss .2 and half-year episode duration are not measured QALYs. A scenario declines this transfer; alternative MotherWise utility scenarios replace, rather than add to, overlapping La Luz health. WiseWellness and Incredible Years have no native unique completed cohort here and remain unknown. Marketing preterm-birth reductions are not imported as all-recipient effects.
4. What do you get for your dollar?
The reference now matches FY2023 full cost $1,411,532 with its 567 enrolled-person envelope, instead of pairing FY2024 costs with FY2023 output. Latest reviewed FY2024 full cost remains $1,929,744 ($1,899,069 functional plus $30,675 netted events); FY2022 is $952,412. Their comparable three-year mean is $1,431,229.33. FY2024 cost with historical output is an explicit capacity/vintage sensitivity, not observed 2024 productivity. Recognized FY2023 program cost $1,198,960 omits allocated overhead and is not a full prevention or gift price. Current conditional health is 0.413395 years, signed household resources -0.219062 equivalents, and price $7.3M versus historical alpha $5.8M. The change reflects matched costing, patient-versus-household units and removal of ungated work gains, not measured deterioration. Whole-recipient cost includes broader unquantified services. No allocated current La Luz full cost or next-gift recipient expansion response is observed.
Model, assumptions and sensitivity
Matched historical FY2023 whole recipient annual cost against a conditional La Luz prevention subset; not whole-portfolio or marginal-gift expected value.
Ten-county CBSA19740, boundary OMB-23-01-2023-07-21. Beneficiary local share 0.9 is judgment, not headquarters attribution; broader Colorado clients excluded proportionally once.
Health = (person N × b × eligible × local dose/fidelity transport × transferred absolute risk difference × episode utility × finite discounted T − ALL enrolled person harm) × local share. Resource households = N × unique; changed illness households share b × eligible × local dose/fidelity transport × risk difference. Joint net household gains minus full access costs use .5 log(1 + net resources / baseline); distinct global payer losses on local transfers once. MotherWise alternate utility replaces La Luz; positive-only overlap never erases negative health.
- C
- 1411532 USD annual (observed). Observed original FY2023 whole recipient full annual functional expense plus netted events; matched to historical enrollment. [finance2023]
- N
- 567 historical annual enrolled persons (observed). Observed 567 enrolled participants in FY2023 original filing, not unique completed preventive cases. [finance2023]
- unique
- 0.9 households per enrolled person (judgment). Judged household grouping only; does not reduce distinct clinical persons. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- eligible
- 0.25 model parameter (judgment). Explicit conditional finite scope hypothesis; native local causal coefficient unmeasured and stress-tested. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- completion
- 0.7 model parameter (judgment). Legacy parameter name; judged .7 local dose/fidelity transport factor relative to ROSE trial assignment, not a second observed completion adjustment. The .15 trial effect is ITT, not per-completer. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- b
- 0.5 model parameter (judgment). Explicit conditional finite scope hypothesis; native local causal coefficient unmeasured and stress-tested. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- response
- 0.15 model parameter (judgment). Original prenatal ROSE ITT absolute six-month incidence difference .15 transferred conditionally to a judged local subgroup; no local calibration. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- q
- 0.2 model parameter (judgment). Judged .2 utility loss during depression; original prevention trial did not measure utility. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- T
- 0.5 model parameter (judgment). Judged half-year episode duration, not measured integrated QALY. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- g
- 0.9 model parameter (judgment). Explicit conditional finite scope hypothesis; native local causal coefficient unmeasured and stress-tested. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- delay
- 0.1 model parameter (judgment). Explicit conditional finite scope hypothesis; native local causal coefficient unmeasured and stress-tested. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- r
- 0.03 model parameter (judgment). Explicit conditional finite scope hypothesis; native local causal coefficient unmeasured and stress-tested. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- harm
- 0.0005 model parameter (judgment). Explicit conditional finite scope hypothesis; native local causal coefficient unmeasured and stress-tested. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- workGain
- 0 model parameter (judgment). Central zero net illness work resources, with signed sensitivities; no direct MotherWise earnings effect established. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- medicalGain
- 200 model parameter (judgment). Judged $200 actual otherwise-paid illness care avoided only when depression is prevented; no retail care value. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- overlap
- 0.5 model parameter (judgment). Explicit conditional finite scope hypothesis; native local causal coefficient unmeasured and stress-tested. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- cost
- 30 model parameter (judgment). Judged $30 NET additional household participation/time cost relative to usual care; full even failed prevention. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- baseline
- 30000 model parameter (judgment). Explicit conditional finite scope hypothesis; native local causal coefficient unmeasured and stress-tested. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- payerLoss
- 0 model parameter (judgment). Explicit conditional finite scope hypothesis; native local causal coefficient unmeasured and stress-tested. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- externalCost
- 0 model parameter (judgment). Explicit conditional finite scope hypothesis; native local causal coefficient unmeasured and stress-tested. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- payerPeople
- 10000 model parameter (judgment). Explicit conditional finite scope hypothesis; native local causal coefficient unmeasured and stress-tested. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- payerBaseline
- 50000 model parameter (judgment). Explicit conditional finite scope hypothesis; native local causal coefficient unmeasured and stress-tested. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- motherQ
- 0 model parameter (judgment). Central omitted/unmeasured MotherWise utility; alternate hypotheses replace La Luz and are not empirical effects. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
- motherOverlap
- 1 model parameter (judgment). Positive-only health overlap for alternate MotherWise utility; negative health retained in full. [services] [dose] [rose-trial] [motherwise-rct] [cg-cost]
central: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.22. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
clinical null: Cost: $1.4M; Denver health QALYs: -0.25; all-population health QALYs: -0.28. Income-equivalent healthy years: -0.22. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
financial only: Cost: $1.4M; Denver health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: -0.22. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
zero benefit full burdens: Cost: $1.4M; Denver health QALYs: -0.25; all-population health QALYs: -0.28. Income-equivalent healthy years: -0.23. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
no exposure: Cost: $1.4M; Denver health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
no gift no exposure: Cost: $0; Denver health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
adverse: Cost: $1.4M; Denver health QALYs: -2.61; all-population health QALYs: -2.90. Income-equivalent healthy years: -0.27. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
unknown: Cost: unknown; Denver health QALYs: unknown; all-population health QALYs: unknown. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
no illness resources: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.23. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
clinical response null: Cost: $1.4M; Denver health QALYs: -0.25; all-population health QALYs: -0.28. Income-equivalent healthy years: -0.23. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
short health: Cost: $1.4M; Denver health QALYs: 0.08; all-population health QALYs: 0.09. Income-equivalent healthy years: -0.22. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
one year health: Cost: $1.4M; Denver health QALYs: 1.08; all-population health QALYs: 1.20. Income-equivalent healthy years: -0.22. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
low additionality: Cost: $1.4M; Denver health QALYs: -0.12; all-population health QALYs: -0.13. Income-equivalent healthy years: -0.23. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
all additionality: Cost: $1.4M; Denver health QALYs: 1.08; all-population health QALYs: 1.20. Income-equivalent healthy years: -0.21. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
half geography: Cost: $1.4M; Denver health QALYs: 0.23; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.12. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
no local share: Cost: $1.4M; Denver health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
no positive overlap: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.23. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
full positive overlap: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.21. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
negative overlap zero: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.28. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
negative overlap one: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.28. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
mixed resources: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.24. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
no access cost: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: 0.01. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
high access cost: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -1.52. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
payer transfer loss: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.28. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
external care cost: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.73. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
double cost: Cost: $2.8M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.22. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
matched program recognized cost: Cost: $1.2M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.22. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
latest fy2024 cost historical output: Cost: $1.9M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.22. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
three full year cost mean: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.22. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
half cohort: Cost: $1.4M; Denver health QALYs: 0.21; all-population health QALYs: 0.23. Income-equivalent healthy years: -0.11. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
undated growth envelope: Cost: $1.4M; Denver health QALYs: 0.51; all-population health QALYs: 0.57. Income-equivalent healthy years: -0.27. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
household deduplication: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.17. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
no household resources: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: 0.00. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
net illness work positive: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.19. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
net illness work negative: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.27. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
no eligible subgroup: Cost: $1.4M; Denver health QALYs: -0.25; all-population health QALYs: -0.28. Income-equivalent healthy years: -0.23. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
no completed dose: Cost: $1.4M; Denver health QALYs: -0.25; all-population health QALYs: -0.28. Income-equivalent healthy years: -0.23. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
low transferred risk difference: Cost: $1.4M; Denver health QALYs: -0.03; all-population health QALYs: -0.04. Income-equivalent healthy years: -0.23. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
decline prenatal to postpartum transfer: Cost: $1.4M; Denver health QALYs: -0.25; all-population health QALYs: -0.28. Income-equivalent healthy years: -0.23. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
motherwise utility hypothesis replaces la luz: Cost: $1.4M; Denver health QALYs: 0.64; all-population health QALYs: 0.71. Income-equivalent healthy years: -0.23. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
motherwise adverse hypothesis: Cost: $1.4M; Denver health QALYs: -1.14; all-population health QALYs: -1.27. Income-equivalent healthy years: -0.23. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
negative mother overlap zero: Cost: $1.4M; Denver health QALYs: -1.14; all-population health QALYs: -1.27. Income-equivalent healthy years: -0.23. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
negative mother overlap one: Cost: $1.4M; Denver health QALYs: -1.14; all-population health QALYs: -1.27. Income-equivalent healthy years: -0.23. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
unique zero external resource: Cost: $1.4M; Denver health QALYs: 0.41; all-population health QALYs: 0.46. Income-equivalent healthy years: -0.51. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
one year delay: Cost: $1.4M; Denver health QALYs: 0.40; all-population health QALYs: 0.45. Income-equivalent healthy years: -0.21. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
Counterfactual: Usual prenatal/postpartum care, covered therapy, other parenting groups and household support without this recipient. Trial controls received usual care; recipient additionality and local transfer remain uncertain.
Attribution: Additionality .5, eligible .25 and Denver share .9 are hypotheses, not local causal estimates. ROSE .15 is intention-to-treat absolute incidence difference, NOT completed-dose efficacy. The legacy completion .7 parameter is explicitly a judged local dose/fidelity transport factor relative to trial assignment, not a second empirical completion rate or a per-completer risk difference. Direct MotherWise evidence does not calibrate a positive work or QALY gain.
A matched historical conditional reference, not a whole-portfolio expected value. Native La Luz dose/eligibility, current completed cohort, utility, care savings, additionality and donor capacity remain decision-changing uncertainties. MotherWise/therapy/parenting omitted-channel effects unknown, not empirically zero.
Sensitivity
- clinical null: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- financial only: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- zero benefit full burdens: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- no exposure: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- no gift no exposure: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- adverse: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- unknown: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- no illness resources: $7.7M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- clinical response null: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- short health: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- one year health: $1.6M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- low additionality: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- all additionality: $1.6M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- half geography: $13.1M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- no local share: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- no positive overlap: $7.7M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- full positive overlap: $6.9M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- negative overlap zero: $10.6M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- negative overlap one: $10.6M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- mixed resources: $8.3M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- no access cost: $3.3M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- high access cost: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- payer transfer loss: $10.5M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- external care cost: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- double cost: $14.5M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- matched program recognized cost: $6.2M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- latest fy2024 cost historical output: $9.9M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- three full year cost mean: $7.4M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- half cohort: $14.5M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- undated growth envelope: $5.9M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- household deduplication: $5.8M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- no household resources: $3.4M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- net illness work positive: $6.4M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- net illness work negative: $9.8M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- no eligible subgroup: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- no completed dose: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- low transferred risk difference: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- decline prenatal to postpartum transfer: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- motherwise utility hypothesis replaces la luz: $3.5M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- motherwise adverse hypothesis: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- negative mother overlap zero: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- negative mother overlap one: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- unique zero external resource: no finite positive estimate. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
- one year delay: $7.5M per DALY. Matched FY2023 whole recipient cost and enrolled-person envelope; hypothetical La Luz-compatible subgroup and finite depression prevention. Direct MotherWise RCT does not measure utility/net earnings; additional channels unknown, not zero. Clinical persons distinct from resource households; all negative participation costs retained.
Unresolved inputs
- Current unique completed La Luz participants and eligible local households
- Matched fiscal-year program budgets and outcomes
- Recipient causal utility, episode duration and net income effects
- Donor-relevant next-gift capacity and fully allocated prevention costs
Health and income breakdown
For the modeled $1.4M: 0.41 health QALYs + -0.22 income-equivalent healthy years in Denver: $7.3M per DALY. Income equivalents are welfare comparisons, not observed QALYs or DALYs.
5. Funding and previous grants
Original direct MotherWise results do not establish incremental earnings; central work gain is zero, with positive and negative net caregiver illness-work sensitivities after taxes, benefit withdrawal and work costs. A judged $200 otherwise-paid illness care saving is conditional on the same additional eligible prevention, judged local dose/fidelity transport factor and .15 trial ITT incidence gate; it is not retail counseling value or measured local savings. Declining trial effect or local dose/fidelity transport removes dependent illness savings, while all exposed households retain $30 judged NET additional time/access cost relative to usual services despite provided transport/childcare. Clinical people use N directly; only household resources use .9 grouping. All enrolled people retain judged stress harm independent of prevention success. Same household-year cash/work gains and access costs are jointly logged, with .5 overlap applied only to positives; all losses remain full. Distinct global payer/provider losses associated with local recipients are tested once, assuming payers are separate households; additional provider resources must not duplicate expenses already in C. Delay .1 is engagement onset for costs and effects, not capitalized future loss. Denver .9 share is a judgment, not headquarters attribution. The $1.0M state-financed building is capital capacity, not household income. The own holiday page still links the recipient ColoradoGives profile; no donation transaction or current matched checkout expansion was tested.
Annual expenses
Organization-level spending, including programs, administration and fundraising. The research list averages three comparable, consecutive full fiscal years when available.
- FY 2024: $1.9M; ein:84-1993572, 12-month period, IRS full functional expenses plus netted direct event expenses. Source
- FY 2023: $1.4M; ein:84-1993572, 12-month period, IRS full functional expenses plus netted direct event expenses. Source
- FY 2022: $952K; ein:84-1993572, 12-month period, IRS full functional expenses plus netted direct event expenses. Source
6. Sources
- Thriving Families original FY2024 IRS990. IRS original filing. Published: not stated; retrieved: 2026-10-07.
- Original FY2023 IRS990 and enrollment. IRS original filing. Published: not stated; retrieved: 2026-10-07.
- Original FY2022 IRS990. IRS original filing. Published: not stated; retrieved: 2026-10-06.
- Current recipient programs. Thriving Families. Published: not stated; retrieved: 2026-10-07.
- Current La Luz dose and access supports. Thriving Families. Published: not stated; retrieved: 2026-10-07.
- Original randomized postpartum-depression prevention study. Zlotnick and colleagues / Journal of Affective Disorders. Published: not stated; retrieved: 2026-10-06.
- Recipient ColoradoGives intake and legal identity. Thriving Families. Published: not stated; retrieved: 2026-10-06.
- Current recipient holiday campaign and capital context. Thriving Families. Published: not stated; retrieved: 2026-10-07.
- Health and income cost-effectiveness framework. Coefficient Giving. Published: not stated; retrieved: 2026-10-06.
- Original MotherWise 30-month randomized evaluation. Mathematica / HHS OPRE 2022-240. Published: not stated; retrieved: 2026-10-07.